Targeting RET–interleukin-6 crosstalk to impair metastatic dissemination in breast cancerReport as inadecuate

Targeting RET–interleukin-6 crosstalk to impair metastatic dissemination in breast cancer - Download this document for free, or read online. Document in PDF available to download.

Breast Cancer Research

, 16:301

First Online: 28 January 2014DOI: 10.1186-bcr3608

Cite this article as: Morandi, A. & Isacke, C.M. Breast Cancer Res 2014 16: 301. doi:10.1186-bcr3608


RET rearranged during transfection is a receptor tyrosine kinase overexpressed in a subset of oestrogen receptor ER-positive breast cancers whose expression is regulated by ER signalling. The article from the Hynes group has reported for the first time that RET expression can also be regulated by the inflammatory cytokine IL-6. Importantly, RET and IL-6 interact at a functional level to control migration and the metastatic potential of ER-positive breast cancer cells, in a process that is mediated by FAK activation. Further, targeting RET with receptor tyrosine kinase inhibitors was reported to be more effective than endocrine therapies in impairing metastatic dissemination in vivo, thereby indicating a level of RET regulation that is independent of ER.

AbbreviationsEROestrogen receptor

FAKFocal adhesion kinase

HER2Human epidermal growth factor receptor 2


RETRearranged during transfection.

Electronic supplementary materialThe online version of this article doi:10.1186-bcr3608 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Andrea Morandi - Clare M Isacke


Related documents